Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire Lafitte

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Implementation of optimized supportive care and hospital needs along the management of patients with advanced lung cancerClaire Lafitte, Bénédicte Etienne-Mastroianni, Christelle Fournel, et al.
Cancer Treatment Reviews|August 7, 2024
Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literatureAnne-Laure Désage, Michael Duruisseaux, Claire Lafitte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2022
Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring <i>HER2</i> Mutations: Results From the IFCT-1703 R2D2 TrialJulien Mazieres, Claire Lafitte, Charles Ricordel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 22, 2023
Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRAS<sup>G12C</sup>-Mutant Lung CancerAli Chour, Julie Denis, Céline Mascaux, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Implementation of optimized supportive care and hospital needs along the management of patients with advanced lung cancerClaire Lafitte, Bénédicte Etienne-Mastroianni, Christelle Fournel, et al.
Cancer Treatment Reviews|August 7, 2024
Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literatureAnne-Laure Désage, Michael Duruisseaux, Claire Lafitte, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2022
Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non-Small-Cell Lung Cancer Harboring <i>HER2</i> Mutations: Results From the IFCT-1703 R2D2 TrialJulien Mazieres, Claire Lafitte, Charles Ricordel, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 22, 2023
Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRAS<sup>G12C</sup>-Mutant Lung CancerAli Chour, Julie Denis, Céline Mascaux, et al.
Pageof 1